The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918
Abstract
PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate–binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(−/−) P-glycoprotein (P-gp) knockout and wild-type mice. GF120918 is a potent inhibitor of BCRP and P-gp. The aim was to increase the bioavailability of topotecan by GF120918. PATIENTS AND METHODS: In cohort A, eight patients received 1.0 mg/m 2 oral topotecan with or without coadministration of one single oral dose of 1,000 mg GF120918 (day 1 or day 8). In cohort B, eight other patients received 1.0 mg/m 2 intravenous topotecan with or without 1,000 mg oral GF120918 to study the effect of GF120918 on the systemic clearance of topotecan. RESULTS: After oral topotecan, the mean area under the plasma concentration-time curve (AUC) of total topotecan increased significantly from 32.4 ± 9.6 μg·h/L without GF120918 to 78.7 ± 20.6 μg·h/L when GF120918 was coadministered (P = .008). The mean maximum plasma concentration of total topotecan increased from 4.1 ± 1.5 μg/L without GF120918 to 11.5 ± 2.4 μg/L with GF120918 (P = .008). The apparent bioavailability in this cohort increased significantly from 40.0% (range, 32% to 47%) to 97.1% (range, 91% to 120%) (P = .008). Interpatient variability of the apparent bioavailability was 17% without and 11% with GF120918. After intravenous administration of topotecan, coadministration of oral GF120918 had a small but statistically significant effect on the AUC and systemic clearance of total topotecan but no statistically significant effect on maximum plasma concentration and terminal half-life of total topotecan. CONCLUSION: Coadministration of the BCRP and P-gp inhibitor GF120918 resulted in a significant increase of the systemic exposure of oral topotecan. The apparent oral bioavailability increased from 40.0% without to 97.1% with GF120918.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
Self-citationvon Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., Clark, P. I., Palmer, M. C., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Jonker, J. W. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1651 · Cited by 638
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp, M. C., Floot, B. G., & Schellens, J. H. M. (1999) · PubMed · Cited by 487
Self-citationA kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some Analogues
Fassberg, J., & Stella, V. J. (1992) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600810718 · Cited by 464
Allen, J. D., Brinkhuis, R. F., Wijnholds, J., & Schinkel, A. H. (1999) · PubMed · Cited by 353
DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.
Hsiang, Y. H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., & Potmĕsil, M. (1989) · PubMed · Cited by 339
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
de Bruin, M., Miyake, K., Litman, T., Robey, R., & Bates, S. E. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00182-2 · Cited by 298
Maliepaard, M., van Gastelen, M. A., Tohgo, A., Hausheer, F. H., van Waardenburg, R. C. A. M., de Jong, L. A., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2001) · PubMed · Cited by 231
Self-citation
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Austin Doyle, L., & Ross, D. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206938 · Cited by 1,051
Jonker, J. W., Buitelaar, M., Wagenaar, E., van der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plösch, T., Kuipers, F., Elferink, R. P. J. O., Rosing, H., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202607599 · Cited by 822
Self-citationThe Role of ABC Transporters in Clinical Practice
Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817
Sarkadi, B., Homolya, L., Szakács, G., & Váradi, A. (2006) · Physiological Reviews · doi:10.1152/physrev.00037.2005 · Cited by 726
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 653
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
Szakács, G., Váradi, A., Özvegy-Laczka, C., & Sarkadi, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.010 · Cited by 569
Role of the breast cancer resistance protein (ABCG2) in drug transport
Mao, Q. (2005) · The AAPS Journal · doi:10.1208/aapsj070112 · Cited by 405
Eckardt, J. R., von Pawel, J., Pujol, J.-L., Papai, Z., Quoix, E., Ardizzoni, A., Poulin, R., Preston, A. J., Dane, G., & Ross, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3998 · Cited by 393
ABCG2: determining its relevance in clinical drug resistance
Robey, R. W., Polgar, O., Deeken, J., To, K. W., & Bates, S. E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9042-6 · Cited by 387
Expression and function of efflux drug transporters in the intestine
Takano, M., Yumoto, R., & Murakami, T. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.005 · Cited by 356
Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition
Robey, R. W., Steadman, K., Polgar, O., Morisaki, K., Blayney, M., Mistry, P., & Bates, S. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3298 · Cited by 350
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Intestinal drug transporters: An overview
Estudante, M., Morais, J. G., Soveral, G., & Benet, L. Z. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.042 · Cited by 330
Breedveld, P., Beijnen, J. H., & Schellens, J. H. M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.009 · Cited by 323
Self-citationMizuarai, S., Aozasa, N., & Kotani, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.11669 · Cited by 318
Intestinal permeability and its relevance for absorption and elimination
Lennernäs, H. (2007) · Xenobiotica · doi:10.1080/00498250701704819 · Cited by 304
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain
Agarwal, S., Sane, R., Oberoi, R., Ohlfest, J. R., & Elmquist, W. F. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001888 · Cited by 292
Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284
Self-citationABCG2 – a transporter for all seasons
Sarkadi, B., Özvegy-Laczka, C., Német, K., & Váradi, A. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.03.123 · Cited by 282
Imai, Y., Tsukahara, S., Asada, S., & Sugimoto, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0078 · Cited by 280
Beijnen, J. H., & Schellens, J. H. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01528-1 · Cited by 278
Self-citationPavek, P., Merino, G., Wagenaar, E., Bolscher, E., Novotna, M., Jonker, J. W., & Schinkel, A. H. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073916 · Cited by 278
de Vries, N. A., Zhao, J., Kroon, E., Buckle, T., Beijnen, J. H., & van Tellingen, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1335 · Cited by 270
Self-citationFUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA
Kobayashi, D., Ieiri, I., Hirota, T., Takane, H., Maegawa, S., Kigawa, J., Suzuki, H., Nanba, E., Oshimura, M., Terakawa, N., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001628 · Cited by 268
Wu, C., Calcagno, A. M., & Ambudkar, S. V. (2008) · Current Molecular Pharmacology · doi:10.2174/1874-470210801020093 · Cited by 259
Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin
Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., & Sugiyama, Y. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014019 · Cited by 256
Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges
Shukla, S., Wu, C.-P., & Ambudkar, S. V. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.2.205 · Cited by 253
The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids
Holland, M. L., Lau, D. T. T., Allen, J. D., & Arnold, J. C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707467 · Cited by 150
Lai, J.-I., Tseng, Y.-J., Chen, M.-H., Huang, C.-Y. F., & Chang, P. M.-H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.561936 · Cited by 144
“Similarly, in another early phase trial, elacridar significantly elevated the oral bioavailability of topotecan to more than 2 fold when used in combination with oral topotecan (42), although blood topotecan levels was still lower than the levels of intravenous topotecan.”
BackgroundNovel strategies to reverse chemoresistance in colorectal cancer
Ma, S., Zhang, J., Yan, T., Miao, M., Cao, Y., Cao, Y., Zhang, L., & Li, L. (2023) · Cancer Medicine · doi:10.1002/cam4.5594 · Cited by 108
Robey, R. W., Shukla, S., Steadman, K., Obrzut, T., Finley, E. M., Ambudkar, S. V., & Bates, S. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0811 · Cited by 61
Metadata
- Authors
- Kruijtzer, C. M. F., Beijnen, J. H., Rosing, H., ten Bokkel Huinink, W. W., Schot, M., Jewell, R. C., Paul, E. M., & Schellens, J. H. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-07-01
- Volume
- 20
- Issue
- 13
- Pages
- 2943-2950
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166082449
- Cited by
- 464
- References
- 24
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.